Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
NCT06226805 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BB-031
Study Locations (20)
California
- Mills Peninsula Medical Center — Burlingame
- MemorialCare Long Beach Medical Center — Long Beach
- California Pacific Medical Center — San Francisco
- Pacific Neurosciences Institute at Saint John's Physician Partners — Torrance
Ohio
- The Ohio State University — Columbus
- ProMedica Toledo Hospital — Toledo
- Mercy Health St. Vincent Medical Center — Toledo
Texas
- Valley Baptist Medical Center - Harlingen — Harlingen
- Memorial Hermann Hospital — Houston
Victoria
- Monash Medical Centre — Clayton
- The Royal Melbourne Hospital — Parkville
Arizona
- HonorHealth Bob Bove Neuroscience Institute — Scottsdale
Florida
- Baptist Health Medical Center — Jacksonville
Michigan
- Henry Ford Hospital — Detroit
Missouri
- Washington University in St. Louis — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06226805
The ClinicalTrials.gov registry entry for NCT06226805 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basking Biosciences, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06226805 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Ohio, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06226805 about?
NCT06226805 is a clinical study titled "Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)". The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug...
What is the current status of trial NCT06226805?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2024-07-31. Estimated completion is 2027-09.
What conditions does trial NCT06226805 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06226805?
The interventions under investigation include: Placebo (DRUG), BB-031 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06226805?
This trial is sponsored by Basking Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06226805 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.